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ABSTRACT 
This paper emphasizes on a new simple, accurate, rapid and precise Isocratic Reverse Phase HPLC method  for Simultaneous Estimation and Validation of 
Montelukast sodium and Rupatadine fumarate in Tablet formulation.The Method was performed on Shimadzu-10AT HPLC system using YMC Pack pro-C4 
butyl column-3u particle size(150x4.6mm id) and flow rate of 1ml/min with a load of 10ul. The mobile phase consists of organic phase as Acetonitrile and 
aqueous phase i.e buffer as Ammonium acetate adjusted to pH-3+0.2 with Acetic acid in the ratio of 80:20. Tailing modifier 1-Octane sulphonic acid was used 
in the experiment. The detection was carried out at 252nm. Retention time for Montelukast and Rupatadine were 3.4min and 4.1min respectively. Linearity 
was calculated over the range of 1-100ug/ml for Montelukast and Rupatadine respectively. The % regression for both drugs found to be at 0.999. Validation 
parameters like accuracy, precision, linearity, robustness, ruggedness were done according to ICH guidelines.    
Keywords: - Montelukast, Rupatadine, Simultaneous Estimation, Isocratic RP-HPLC, Tablet formulation.   
 
INTRODUCTION
  
Montelukast  sodium  is  chemically  2-(1-((1-(3-(2-(7-
chloroquinolin-2-yl)vinyl)phenyl)-3-(2-(2-hydroxypropan-2-
yl)phenyl)propylthio)methyl)cyclopropyl)acetic  acid.  It  is  a 
cysteinyl  leukotriene  receptor  antagonist  and  used  in  the 
treatment of chronic asthma.The individual determination of 
Montelukast or in formulation has been carried out by HPLC, 
LC-MS/MS,  HPTLC,  SPECTROSCOPY.  Rupatadine 
fumarate  is  chemically  8-chloro-6,11-dihydro-11-[1[(5-
methyl-3-pyridinyl)methyl]-4-piperinylidene]-5H-
benzo[5,6]cyclohepta[1,2-b]pyridine fumarate. It is a second 
generation antihistamine and Platelet Activating Factor(PAF) 
antagonist, used in the treatment of allergies. There is only 
individual  determination  of  rupatadine  in  formulation  by 
HPLC,  HPTLC,  TITRIMETRY,  LC-MS/MS, 
SPECTROSCOPY  and  no  simultaneous  estimation  within 
formulation has been reported. Literature survey reveals that 
there is only UV- spectroscopic determination of Montelukast 
and Rupatadine in tablet form, and no HPLC determination 
so  far,  hence  it  is  convenient  to  develop  the  method  for 
Simultaneous  Estimation  and  Validation  for  the  combined 
Tablet formulation. The method describes simple, accurate, 
reproducible  and  economic  isocratic  RP-HPLC  for 
Montelukast and Rupatadine combined tablets
1-3.      
 
Montelukast Sodium    Rupatadine Fumarate 
   
Chemical structures of Montelukast and Rupatadine 
   
MATERIALS & METHODS   
Instrumentation  
The Chromatographic system consisted of a Shimadzu Class 
VP Binary pump LC-10ATVP, SIL-10ADVP Auto sampler, 
CTO-10AVP Column Temperature Oven, SPD-10AVP UV-
Visible  Detector.  All  the  components  of  the  system  are 
controlled  using  SCL-10AVP  System  controller.  Data 
acquisition was done using LC Solutions software Ver 1.23 
SP 1.
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Materials Required  
 Methanol  (HPLC  grade,  Merck  ltd),  Acetonitrile  (HPLC 
grade, merck ltd), Milli-Q water, Ammonium acetate, Acetic 
acid (AR Grade, SD Fine chem ltd), Octane sulphonic acid 
(AR  Grade)  Montelukast  and  Rupatadine  (API  purchased 
from Cosmacls. pharma. Ltd)   
Optimized conditions   
The Mobile phase consisted of 80:20 %(v/v) of Acetonitrile 
&  Ammonium  acetate  buffer  adjusted  to  pH-3+0.2  with 
acetic acid, Octane sulphonic acid used as tailing modifier. 
Operated  on  Isocratic  mode.  The  flow  rate  is  1.0  ml/min. 
chromatographic separation of Montelukast and Rupatadine 
was performed on YMC PACK PRO C4 Column (150 x 4.6 
mm id, 3µm), the wavelength of detection is 252 nm. The 
injection volume is 10µL.  
Standard Stock Solution: 
The stock concentrations of Montelukast and Rupatadine are 
6.54mg/ml,  2.5mg/ml  respectively  using  Methanol:  water 
(70:30) as diluents. From the above solution, Mont-0.765ml 
diluted  to  5ml  and  Rup-2.0ml  diluted  to  5ml  to  get  the 
standard stock of 1000ug/ml each. And finally 50ug/ml each 
were  prepared  and  used  as  standard  solutions  in  the 
experiment.  Stock  and  dilution  preparations  are  well 
sonicated  for  dissolution  and  filtered.  The  standard 
chromatogram  of  Montelukast  and  Rupatadine  shown  in 
figure 1.   
Analysis Of Marketed Formulation:   
Twenty tablets were weighed and crushed to a fine powder. 
An accurately weighed powder sample equivalent to 20mg of 
Montelukast sodium and Rupatadine fumarate into a 100ml 
volumetric flask and about 70ml of diluents and sonicate for 
15min. with intermittent shaking. Dilute to the volume, and 
transfer 1.25ml of this solution to 25ml volumetric flask and 
dilute to volume with diluents and mix. Filter through 0.45u 
nylon  filter  paper.    And  filtrate  was  used  under  the 
chromatographic  conditions.  Area  of  each  peak  was 
measured at selected wavelength. The amount of each drug Ramesh Malothu et al. IRJP 2012, 3 (12) 
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present in the sample was determined by comparison with the 
peak areas that of the standard solutions. The results shown in 
table 1. 
VALIDATION RESULTS
  
System Suitability (SST)  
SST  is  commonly  used  to  verify  resolution,  column 
efficiency, and repeatability of the chromatographic system 
to  ensure  its  adequacy  for  a  particular  analysis.  It  is 
performed by performing 6 injections on a sample mixture 
containing Montelukast and Rupatadine stds. The precision 
of the run is calculated for the peak area & retention times of 
Montelukast and Rupatadine separately. Parameters such as 
tailing  factor,  theoretical  plates  and  resolution  etc.  were 
determined. Results shown in table 2. The system suitability 
parameters for the method are listed below in table 3.
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Linearity & Range   
Linearity  is  the  method  to  obtained  tests  that  are  directy 
proportional  to  the  analyte  concentration  within  a  given 
range. Range of analytical procedure is the interval between 
the  upper  and  lower  concentrations  of  the  analyte  in  the 
analytical  procedure  has  a  suitable  level  of  precision, 
accuracy, linearity.  
Calibration curve standards were prepared in the range of 1-
100ug/ml of Montelukast and Rupatadine respectively. The 
calibration curves of peak areas against concentration were 
found to be linear and correlation coefficient (r) found to be 
0.999  for  Montelukast  and  Rupatadine  respectively.  The 
results  and  the  calibration  graphs  are  shown  below  in  the 
tables 4 and figures 2,3 and inter and intra day precision for 
linearity is shown in tables 5,6. 
Acceptance  Criteria:  The  Correlation  Coefficient  should  be 
not less than 0.999.  
Result: The Correlation  Coefficient  obtained  was  0.999  for 
both drugs which compiles the required acceptance criteria.  
Accuracy    
The Accuracy is determined as the closeness of the calculated 
concentration to the nominal concentration. The Precision is 
the  reproducibility  of  the  data.  The  mean  recoveries  were 
calculated at three different levels i.e at 50%, 100%, 150% 
solutions  made  from  the  standard  solution.  The  %  mean 
recoveries found to be 95.263 for Montelukast and 94.9 for 
Rupatadine results shown in table 7.  
Acceptance criteria: the % mean recovery should be within 
the range of 85-115. 
Result: Results comply with acceptance criteria, and are well 
within the limits. The observed mean % recovery is between 
89.49-106.25  for  Montelukast  and  90.15-102.94  for 
Rupatadine.  
Method Precision 
Precision  is  calculated  by  6  repeated  injections  of  test 
formulation. In this method results are reported in the form of 
%  RSD  values  for  peak  areas  of  all  components  and  are 
within limits. Results shown in table 8.   
Acceptance  criteria:  In  this  precision  method  %  RSD  or 
coefficient of correlation should be < 4 
Specificity  
The Specificity of the method is done by injecting 4 samples 
namely: blank sample, sample with Montelukast Std, sample 
with  Rupatadine  std,  sample  containing  mixture  of 
Montelukast and Rupatadine.  There is no interference in the 
retention time of the Montelukast and Rupatadine. specificity 
chromatograms are shown in figures 4, 5, 6. 
Acceptance  criteria:-An  interference  in  the  peak  area  of  ≤ 
20% at the retention time of the drug in the blank sample. 
Result: There is no interference in the retention time of the 
Montelukast and Rupatadine. 
Room Temperature Stability  
1ml stock solution taken and placed on a bench top allowing 
it to stand at room temperature for a period of atleast 12hrs. 
Stability  of  this  diluted  solution  is  known  from  sample 
freshly injected. The results are shown in tables 10, 11. The 
% stability (after 12 hrs) = (mean peak area ratio of stability 
sample  /  mean  peak  area  ratio  of  fresh  sample)  *  100. 
Validation of proposed methods shown in table 9. 
Result: % stability (after 12 Hrs) = 96.14 for Montelukast and 
89.93 for Rupatadine 
Robustness & Ruggedness 
The Ruggedness of the method is observed by evaluating the 
influence  of  Analyst  variation  &  Column  variation. 
Robustness  is  observed  by  evaluating  the  influence  of 
Flowrate,  Mobile  phase  composition  on  the  developed 
method.  Flowrate  variation,  mobile  phase  composition 
chromatograms shown in figures 7,8,9,10. 
Result:   
a)  At  Flow  rate  of  0.9ml/min  –  late  elution  of  drugs,  Rt 
increases  and  tailing  factor  of  Rupatadine      increases 
across the USP limits. 
b)  At  flow  rate  of  1.1ml/min  -fast  elution  of  drugs,  Rt 
decreases and tailing factor of Rupatadine is very low. 
c)  Mobile  phase  composition:  (85:15)-  Rt  of  Montelukast 
decreases,  and  Rupatadine  increases.  At  (75:25)-  Rt  of 
Montelukast  decreases  and  Rupatadine  with  normal 
elution. 
d)   With column and analyst variation, there is no change in 
Retention time or peak intensities. Hence the method is 
said to be robust and rugged. 
Stress Degradation Studies   
For Stress degradation analysis, aliquots of stock are treated 
separately with 100 μL of 0.1N HCl (Acid Stability), 0.1N 
NaOH  (Alkaline  Stability),  5%  v/v  Hydrogen  Peroxide 
(Oxidative  Stress),  for  24  Hrs.  Samples  for  Photo-
degradation are placed in a transparent glass vial & placed in 
a UV chamber for 24 Hrs. Samples are then diluted suitably 
to  obtain  a  sample  within  the  linear  calibration  range.  
Stability of these samples are compared with fresh sample on 
the day of analysis. Photolytic and alkaline stress degradation 
chromatograms shown in figures 11,12   
Acceptance criteria: - The active peak of drug should not have 
flag in the results.  And  should  be  stable  enough in all the 
above stress conditions. 
Result:- Montelukast is unstable with light producing very low 
peak area, and split in peak appeared in presence of alkali. 
Rupatadine is stable , and low peak area observed in Alkaline 
state.Hence,  Montelukast  is  photosensitive  and  alkaline 
instable drug whereas Rupatadine is only alkaline instable.   
 
Table 1: Analysis of marketed formulation data of Montelukast and Rupatadine 
Drug Name  Label claim(mg)  Amount Found(mg)  % Assay 
 
Montelukast 
 
10 
 
10.21 
 
102.10 
Rupatadine  10  10.18  101.77 
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Table 2: System suitability data of Montelukast and Rupatadine 
Sample ID  Montelukast peak retention time  Montelukast peak area  Rupatadine peak retention time  Rupatadine peak area 
1  3.47  1106764  4.05  2110734 
2  3.47  1069245  4.07  2010549 
3  3.46  1095721  4.07  2037658 
4  3.48  1091476  4.1  2107638 
5  3.48  1075051  4.11  1999715 
6  3.49  1087024  4.13  2075484 
Mean  3.475  1087546.83  4.088  2056963 
SD  0.0105  13732.6702  0.0299  48180.0362 
% CV  0.3  1.26  0.73  2.34 
 
Table 3: System Suitability Parameters of Montelukast and Rupatadine 
S.No  Parameters  Montelukast  Rupatadine 
1  Tailing factor  1.411  1.816 
2  Retention time  3.48  4.1 
3  Resolution  0.00  6.85 
4  Theoretical plates  17206  8974 
 
Table 4: Linearity Data of Montelukast and Rupatadine 
Sample ID  Montelukast Conc(ug/ml)  Montelukast peak area  Rupatadine conc(ug/ml)  Rupatadine peak   area 
1  1  10769  1  23985 
2  5  99826  5  224869 
3  10.01  208044  10  462247 
4  20.01  428259  20  963631 
5  40.02  888754  40  1912261 
6  60.04  1382032  60  2847194 
7  80.05  1770479  80  3882653 
8  100.06  2199642  100  4894059 
 
Table 5: Summary of Montelukast linear calibration curve showing inter and intraday Precision 
Sample ID  1  5  10.01  20.01  40.02  60.04  80.05  100.06  y-intercept  slope  r 
2 
PA-1  1.23  5.11  10.11  20.19  40.04  60.1  81.09  100.11  7974  22302  0.999 
PA-2  1.22  5.12  10.17  20.11  40.16  60.14  81.12  100  11583  23009  0.999 
PA-3  1.21  5.14  10.15  20.16  40.11  60.01  80.99  100.22  11931  23699  0.999 
Mean  1.22  5.123  10.143  20.153  40.103  60.083  81.067  100.11  10496  23003.33  0.999 
SD  0.01  0.0153  0.0306  0.0404  0.0603  0.0666  0.0681  0.11       
% CV  0.82  0.3  0.3  0.2  0.15  0.11  0.08  0.11       
 
Table 6: Summary of Rupatadine linear calibration curve showing inter and intra day Precision 
Sample ID  1  5  10  20  40  60  80  100  y-intercept  slope  r 
2 
PA-1  1.12  5.04  10.01  20.08  40.03  60.06  80.08  100.02  30030  48896  0.999 
PA-2  1.15  5.09  10.09  20.1  40.05  60.11  80.14  100.15  32309  48854  0.999 
PA-3  1.17  5.06  10.05  20.12  40.09  60.09  80.02  100.09  46640  51511  0.999 
Mean  1.147  5.063  10.05  20.1  40.057  60.087  80.08  100.087  36326.3  49753.667  0.999 
SD  0.0252  0.0252  0.04  0.02  0.0306  0.0252  0.06  0.0651       
% CV  2.19  0.5  0.4  0.1  0.08  0.04  0.07  0.07       
 
Table 7: Accuracy data of Montelukast and Rupatadine 
  Montelukast  Rupatadine 
Spike level  % recovery  Mean % recovery  % recovery  Mean % recovery 
50%  105.77   
106.25 
98.12   
102.94  50%  106.06  105.47 
50%  106.92  105.24 
100%  89.06   
90.05 
89.04   
90.15  100%  89.06  91.16 
100%  89.06  90.26 
150%  90.33   
89.49 
92.54   
91.61 
 
150%  89.35  91.83 
150%  88.8  90.47 
 
Table 8: Method precision data of Montelukast and Rupatadine 
S.No  % Assay of Montelukast  % Assay of Rupatadine 
1  102.51  101.52 
2  101.60  101.82 
3  102.20  101.97 
4  102.51  101.82 
5  102.50  101.52 
6  101.60  101.97 
average  102.10  101.77 
% RSD  0.45  0.23 
Table 9: Validation of the proposed methods 
  Montelukast  Rupatadine 
Linearity & range  1-100ug/ml  1-100ug/ml 
Intercept  7974  300300 
Slope  22302  48896 
Correlation coefficient  (r)  0.999  0.999 Ramesh Malothu et al. IRJP 2012, 3 (12) 
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Table 10: RT stability data of Montelukast 
Fresh sample  Stability sample 
SR NO  Retention time  Peak Area  Retention time  Peak Area 
1  3.5  1166761  3.49  1105631 
2  3.47  1193889  3.49  1092083 
3  3.47  1192773  3.45  1103114 
4  3.47  1184391  3.46  1201998 
5  3.47  1182095  3.47  1006380 
6  3.46  1144855  3.5  1167335 
Mean    1170447    1125237 
 
Table 11: RT stability data of Rupatadine 
Fresh sample  Stability sample 
SR NO  Retention time  Peak Area  Retention time  Peak Area 
1  4.32  2267007  4.29  2281257 
2  4.29  2478154  4.3  2164340 
3  4.3  2501007  4.27  2184958 
4  4.3  2477441  4.28  2514492 
5  4.3  2431677  4.3  1879722 
6  4.29  2476353  4.32  2247171 
Mean    2461823.6    2213795 
 
 
Figure 1: Chromatogram of Montelukast and Rupatadine standards 
Montelukast-Rt-3.42      Rupatadine-Rt-4.12 
 
 
Figure 2: Linearity plot of Montelukast 
 
 
Figure 3: Linearity plot of Rupatadine 
 
 
Figure 4: Specificity chromatogram of Blank sample 
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Figure 5: Specificity Chromatogram of Montelukast 
 
 
Figure 6: Specificity Chromatogram of Rupatadine 
 
 
Figure 7: Flow Rate Variation (0.9ml/Min) Of Montelukast and Rupatadine 
 
 
Figure 8: Flow Rate Variation (1.1ml/Min) Of Montelukast and Rupatadine 
 
 
Figure 9: Mobile Phase Variation (85:15) of Montelukast and Rupatadine 
 
 
Figure 10: Mobile Phase Variation (75:25) of Montelukast and Rupatadine 
 
 
Figure 11: Photolytic Stress Degradation of Montelukast 
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Figure 12: Alkaline Stress Degradation of Montelukast 
 
DISCUSSION
  
A new, Reversed-phase HPLC method has been developed 
for  Simultaneous  Estimation  of  Montelukast  sodium  and 
Rupatadine fumarate in a Tablet formulation. It was shown 
that the method was accurate, reproducible, repeatable, linear, 
precise and selective, proving the reliability of the method. 
The run time is relatively short , i.e. 6 min, which enables 
rapid quantitation of  many samples in routine and Quality 
Control  analysis  of  Tablet  formulations.  The  method 
employed is isocratic and the results show the method could 
find  practical  application  as  a  quality-control  tool  for 
simultaneous  estimation  of  two  drugs,  Montelukast  and 
Rupatadine  from  their  combined  dosage  forms  in  Quality-
control laboratories
16-21. 
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